ResMed released strong Q2 2018 sales +11% y/y and adjusted EPS +37%. Our patience in Resmed early last year paid off, as the prior production issues have been resolved, lifting mask sales in the double digit range. The company will benefit from the US tax reform this year, lifting EPS by 13%. However this is a one-time event as FY19 will be impacted by the Australian taxation. We are raising our price target to $97 and maintaining our position in the stock. Continue reading “Resmed 2Q18 earnings results: strength continues for FY18”